Methods and compositions for alleviating stuttering
Patent 6855721 Issued on February 15, 2005. Estimated Expiration Date: July 28, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/300, Plural hetero atoms in the bicyclo ring system424/468, Sustained or differential release type424/419, Natural or synthetic resin424/488, Polysaccharides (e.g., cellulose, etc.)424/497, Containing solid synthetic polymers424/480, Cellulose or derivative546/122, The other cyclo in the bicyclo ring system is also six-membered (e.g., naphthyridines, etc.)210/198.2Chromatography
Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and 2-(7-chloro-1,8-naphthyridin-2y1)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.
Other References
Sandyk, International Journal of Neuroscience, 1995, 83(1-2): 81-92.*
Doble et al. “RP 59037 and RP 60503: Anxiolytic Cyclopyrrolone Derivatives with low sedative ptential. Interaction with the gamma-amminobutyric AcidA/ Benzodiazepine receptor complex and behavorial effects in the rode” J Pharmacol Exp Ther 266(3):1213-26.*
Sandyk,Medline Abstract AN:96357641 of International Journal of neuroscience, 1995, 83(1-2):81-92.*
Brady et al. 1991 “The Pharmacology of Stuttering: A Critical Review” Am J Psychiatry 148:1309-1316.
Wells et al. 1971 “Control Trial of the Treatment of 36 Stutterers” Brit. J. Psychiat. 119: 603-4.
Rentschler et al. 1984 “The Onset of Stuttering Following Drug Overdose” J. Fluency Disord. 9: 265-284.
Brewerton et al. 1996 “Stuttering With Sertaline” J Clin Psychiatry 57(2):90-1.
Vink et al. 1992 “Clonidine and stuttering” Am J. Psychiatry 149(5):717-8.
Costa 1992 “Antidepressants and the treatment of stuttering” Am J Psychiatry 149(9):1281.
Christensen et al. 1996 “A Case of Sertraline-Induced Stuttering” J Clin Psychopharmacol 16(1):92-93.
Makela et al. 1996 “Reply [to Christensen et al.]” J Clin Psychopharmacol 16(1):93.
Brady 1992 “Dr. Brady Replies [to Vink et al.]” Am J. Psychiatry 149(56):718.
Brady 1992 “Dr. Brady Replies [to Costa]” Am J. Psychiatry 149(9):1281.
Stager et al. 1995 “Fluency Changes in Persons Who Stutter Following a Double Blind Trial of Clomipramine and Desipramine” J Speech Hear Res. 38:516-25.
Schreiber et al. 1997 “Paroxetine for secondary stuttering: further interaction of serotonin and dopamine” J Nerv Ment Dis. 185(7):465-7.
Fernandez et al. 1995 “Clinical Pharmacokinetics of Zopiclone”; Clin Pharmacokinet, 29(6): 431-41.
Doble et al. 1993 “RP 59037 and RP 60503: Anxiolytic Cyclopyrrolone Derivatives with Low Sedative Potential. Interaction with the γ-Aminobutyric AcidA/Benzodiazepine Receptor Complex and Behavorial Effects in the Rodent” J Pharmacol Exp Ther. 266(3):1213-26.
Korpi et al. 1997“GABAA-receptor Subtypes: Clinical Efficacy and Selectivity of Benzodiazepine Site Ligands” Annals Med 29:275-282; Erratum 1997 Annals Med 29: 275-82.
Kiziltan et al. 1996 “Stuttering May Be a Type of Action Dystonia” Movement Disorders 11(3): 278-282.
Swinyard 1990 “Sedatives and Hypnotics”, Remington's Pharmaceutical Sciences, Gennaro, A.R., 18th Edition, Mack Publishing Co., Easton, PA, pp. 1057-1071.
Di Santo 1990 “Bioavailability and Bioequivalency Testing”, Remington's Pharmaceutical Sciences, Gennaro, A.R., 18th Edition, Mack Publishing Co., Easton, PA, pp. 1451-1458.
Vadas 1990 “Stability of Pharmaceutical Products”, Remington's Pharmaceutical Sciences, Gennaro, A.R., 18th Edition, Mack Publishing Co., Easton, PA, pp. 1504-1512.
July 28, 2020. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
